Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AI vs. neurofibromatosis
July/August 2020
SHARING OPTIONS:

CAMBRIDGE, U.K.—Healx and the Children’s Tumor Foundation (CTF) launched a partnership earlier this year focused on advancing artificial intelligence (AI)-derived therapies for neurofibromatosis (NF), a rare genetic disorder that affects one in 3,000 people globally. The agreement unites Healx’s AI technology and drug discovery expertise with CTF’s disease data, networks and patient insight as the organizations pursue therapies for NF1. There are three types of NF—NF1, NF2 and schwannomatosis—and no treatments exist for any type. Simone Manso, who is a member of CTF’s board of directors and chairman of CTF Europe’s board, will join Healx as head of NF Strategic Partnerships to lead drug discovery work in conjunction with this deal.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.